{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T13:12:54Z","timestamp":1780405974170,"version":"3.54.1"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T00:00:00Z","timestamp":1536278400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s11906-018-0893-8","type":"journal-article","created":{"date-parts":[[2018,9,7]],"date-time":"2018-09-07T04:50:19Z","timestamp":1536295819000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Modulation of Sympathetic Overactivity to Treat Resistant Hypertension"],"prefix":"10.1007","volume":"20","author":[{"given":"Raven","family":"Voora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan L.","family":"Hinderliter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,7]]},"reference":[{"issue":"20","key":"893_CR1","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1001\/jama.2010.650","volume":"303","author":"BM Egan","year":"2010","unstructured":"Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988\u20132008. JAMA. 2010;303(20):2043\u201350. \n                      https:\/\/doi.org\/10.1001\/jama.2010.650\n                      \n                    .","journal-title":"JAMA"},{"issue":"2","key":"893_CR2","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/2211068215605838","volume":"21","author":"JM Moriarty","year":"2016","unstructured":"Moriarty JM, Tung R, Bradfield JS, McWilliams J, Lee EW, Kuo MD. Renal denervation: a novel therapy at the crossroads of imaging, intervention, and innovation. Journal of laboratory automation. 2016;21(2):312\u20136. \n                      https:\/\/doi.org\/10.1177\/2211068215605838\n                      \n                    .","journal-title":"Journal of laboratory automation"},{"issue":"6","key":"893_CR3","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1161\/hypertensionaha.111.170308","volume":"57","author":"SD Persell","year":"2011","unstructured":"Persell SD. Prevalence of resistant hypertension in the United States, 2003\u20132008. Hypertension. 2011;57(6):1076\u201380. \n                      https:\/\/doi.org\/10.1161\/hypertensionaha.111.170308\n                      \n                    .","journal-title":"Hypertension"},{"issue":"4","key":"893_CR4","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1001\/jamacardio.2018.0005","volume":"3","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM. The 2017 American College of Cardiology\/American Heart Association Clinical Practice Guideline for high blood pressure in adults. JAMA cardiology. 2018;3(4):352\u20133. \n                      https:\/\/doi.org\/10.1001\/jamacardio.2018.0005\n                      \n                    .","journal-title":"JAMA cardiology"},{"issue":"40","key":"893_CR5","doi-asserted-by":"publisher","first-page":"2686","DOI":"10.1093\/eurheartj\/ehv392","volume":"36","author":"SF Rimoldi","year":"2015","unstructured":"Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J. 2015;36(40):2686\u201395. \n                      https:\/\/doi.org\/10.1093\/eurheartj\/ehv392\n                      \n                    .","journal-title":"Eur Heart J"},{"issue":"1","key":"893_CR6","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.113.000660","volume":"3","author":"SM Smith","year":"2014","unstructured":"Smith SM, Huo T, Delia Johnson B, Bittner V, Kelsey SF, Vido Thompson D, et al. Cardiovascular and mortality risk of apparent resistant hypertension in women with suspected myocardial ischemia: a report from the NHLBI-sponsored WISE study. J Am Heart Assoc. 2014;3(1):e000660. \n                      https:\/\/doi.org\/10.1161\/jaha.113.000660\n                      \n                    .","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"893_CR7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/HJH.0b013e328363823f","volume":"31","author":"G Brambilla","year":"2013","unstructured":"Brambilla G, Bombelli M, Seravalle G, Cifkova R, Laurent S, Narkiewicz K, et al. Prevalence and clinical characteristics of patients with true resistant hypertension in central and Eastern Europe: data from the BP-CARE study. J Hypertens. 2013;31(10):2018\u201324. \n                      https:\/\/doi.org\/10.1097\/HJH.0b013e328363823f\n                      \n                    .","journal-title":"J Hypertens"},{"issue":"6","key":"893_CR8","first-page":"507","volume":"56","author":"C Tsioufis","year":"2015","unstructured":"Tsioufis C, Dimitriadis K, Tousoulis D. Sympathetic nervous system activation and left ventricular hypertrophy: reflections of the same portrait of resistant hypertension? Hell J Cardiol. 2015;56(6):507\u20139.","journal-title":"Hell J Cardiol"},{"issue":"5","key":"893_CR9","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.jash.2015.01.014","volume":"9","author":"R Modolo","year":"2015","unstructured":"Modolo R, de Faria AP, Moreno H. Resistant hypertension: a volemic or nervous matter? J Am Soc Hypertens. 2015;9(5):408\u20139. \n                      https:\/\/doi.org\/10.1016\/j.jash.2015.01.014\n                      \n                    .","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"893_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.semnephrol.2014.08.009","volume":"34","author":"RV Oliva","year":"2014","unstructured":"Oliva RV, Bakris GL. Sympathetic activation in resistant hypertension: theory and therapy. Semin Nephrol. 2014;34(5):550\u20139. \n                      https:\/\/doi.org\/10.1016\/j.semnephrol.2014.08.009\n                      \n                    .","journal-title":"Semin Nephrol"},{"issue":"5","key":"893_CR11","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.semnephrol.2014.08.004","volume":"34","author":"RR Townsend","year":"2014","unstructured":"\u2022 Townsend RR. Pathogenesis of drug-resistant hypertension. Semin Nephrol. 2014;34(5):506\u201313. \n                      https:\/\/doi.org\/10.1016\/j.semnephrol.2014.08.004\n                      \n                    . Comprehensive review discussing the pathogenesis of resistant hypertension.","journal-title":"Semin Nephrol"},{"issue":"1","key":"893_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.2174\/15701611113119990140","volume":"12","author":"AJ Manolis","year":"2014","unstructured":"Manolis AJ, Poulimenos LE, Kallistratos MS, Gavras I, Gavras H. Sympathetic overactivity in hypertension and cardiovascular disease. Curr Vasc Pharmacol. 2014;12(1):4\u201315.","journal-title":"Curr Vasc Pharmacol"},{"key":"893_CR13","doi-asserted-by":"publisher","first-page":"642416","DOI":"10.4061\/2011\/642416","volume":"2011","author":"C Tsioufis","year":"2011","unstructured":"Tsioufis C, Kordalis A, Flessas D, Anastasopoulos I, Tsiachris D, Papademetriou V, et al. Pathophysiology of resistant hypertension: the role of sympathetic nervous system. Int J Hypertens. 2011;2011:642416\u20137. \n                      https:\/\/doi.org\/10.4061\/2011\/642416\n                      \n                    .","journal-title":"Int J Hypertens"},{"issue":"8","key":"893_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s11906-015-0570-0","volume":"17","author":"D Hering","year":"2015","unstructured":"Hering D, Schlaich M. The role of central nervous system mechanisms in resistant hypertension. Curr Hypertens Rep. 2015;17(8):58. \n                      https:\/\/doi.org\/10.1007\/s11906-015-0570-0\n                      \n                    .","journal-title":"Curr Hypertens Rep"},{"issue":"13","key":"893_CR15","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.2174\/1381612811319130008","volume":"19","author":"RM Bruno","year":"2013","unstructured":"Bruno RM, Di Giulio A, Bernini G, Virdis A, Ghiadoni L, Taddei S. Device-based therapies for resistant hypertension. Curr Pharm Des. 2013;19(13):2401\u20138.","journal-title":"Curr Pharm Des"},{"issue":"1","key":"893_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.5114\/aoms.2010.13500","volume":"6","author":"A Zygmunt","year":"2010","unstructured":"Zygmunt A, Stanczyk J. Methods of evaluation of autonomic nervous system function. Arch Med Sci. 2010;6(1):11\u20138. \n                      https:\/\/doi.org\/10.5114\/aoms.2010.13500\n                      \n                    .","journal-title":"Arch Med Sci"},{"issue":"2","key":"893_CR17","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1152\/japplphysiol.00832.2009","volume":"108","author":"M Esler","year":"2010","unstructured":"Esler M. The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management. J Appl Physiol (Bethesda, Md : 1985). 2010;108(2):227\u201337. \n                      https:\/\/doi.org\/10.1152\/japplphysiol.00832.2009\n                      \n                    .","journal-title":"J Appl Physiol (Bethesda, Md : 1985)"},{"issue":"5","key":"893_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrn1902","volume":"7","author":"PG Guyenet","year":"2006","unstructured":"Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7(5):335\u201346. \n                      https:\/\/doi.org\/10.1038\/nrn1902\n                      \n                    .","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"893_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s11906-008-0045-7","volume":"10","author":"RG Victor","year":"2008","unstructured":"Victor RG, Shafiq MM. Sympathetic neural mechanisms in human hypertension. Curr Hypertens Rep. 2008;10(3):241\u20137.","journal-title":"Curr Hypertens Rep"},{"issue":"5","key":"893_CR20","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jash.2016.02.015","volume":"10","author":"G Grassi","year":"2016","unstructured":"Grassi G, Ram VS. Evidence for a critical role of the sympathetic nervous system in hypertension. J Am Soc Hypertens. 2016;10(5):457\u201366. \n                      https:\/\/doi.org\/10.1016\/j.jash.2016.02.015\n                      \n                    .","journal-title":"J Am Soc Hypertens"},{"issue":"6","key":"893_CR21","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1161\/circresaha.116.303604","volume":"116","author":"G Grassi","year":"2015","unstructured":"Grassi G, Mark A, Esler M. The sympathetic nervous system alterations in human hypertension. Circ Res. 2015;116(6):976\u201390. \n                      https:\/\/doi.org\/10.1161\/circresaha.116.303604\n                      \n                    .","journal-title":"Circ Res"},{"issue":"3","key":"893_CR22","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1161\/hypertensionaha.113.02439","volume":"63","author":"M Esler","year":"2014","unstructured":"Esler M. Sympathetic nervous system moves toward center stage in cardiovascular medicine: from Thomas Willis to resistant hypertension. Hypertension. 2014;63(3):e25\u201332. \n                      https:\/\/doi.org\/10.1161\/hypertensionaha.113.02439\n                      \n                    .","journal-title":"Hypertension"},{"issue":"5","key":"893_CR23","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1113\/expphysiol.2009.047332","volume":"95","author":"JP Fisher","year":"2010","unstructured":"Fisher JP, Fadel PJ. Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension. Exp Physiol. 2010;95(5):572\u201380. \n                      https:\/\/doi.org\/10.1113\/expphysiol.2009.047332\n                      \n                    .","journal-title":"Exp Physiol"},{"issue":"1","key":"893_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000368483","volume":"40","author":"J Skrzypecki","year":"2015","unstructured":"Skrzypecki J, Ufnal M. Drug resistant hypertension\u2014no simple way out. Kidney Blood Press Res. 2015;40(1):66\u201376. \n                      https:\/\/doi.org\/10.1159\/000368483\n                      \n                    .","journal-title":"Kidney Blood Press Res"},{"issue":"5","key":"893_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1524-6175.2007.07161.x","volume":"9","author":"DA Sica","year":"2007","unstructured":"Sica DA. Centrally acting antihypertensive agents: an update. J Clin Hypertens (Greenwich, Conn). 2007;9(5):399\u2013405.","journal-title":"J Clin Hypertens (Greenwich, Conn)"},{"issue":"5","key":"893_CR26","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/00041552-200409000-00006","volume":"13","author":"G Grassi","year":"2004","unstructured":"Grassi G. Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens. 2004;13(5):513\u20139.","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"6","key":"893_CR27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1093\/ajh\/hpw012","volume":"29","author":"G Grassi","year":"2016","unstructured":"Grassi G. Sympathomodulatory effects of antihypertensive drug treatment. Am J Hypertens. 2016;29(6):665\u201375. \n                      https:\/\/doi.org\/10.1093\/ajh\/hpw012\n                      \n                    .","journal-title":"Am J Hypertens"},{"issue":"12","key":"893_CR28","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1111\/eci.12553","volume":"45","author":"G Grassi","year":"2015","unstructured":"Grassi G, Seravalle G, Mancia G. Sympathetic activation in cardiovascular disease: evidence, clinical impact and therapeutic implications. Eur J Clin Investig. 2015;45(12):1367\u201375. \n                      https:\/\/doi.org\/10.1111\/eci.12553\n                      \n                    .","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"893_CR29","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1161\/hypertensionaha.109.147058","volume":"55","author":"DW Wray","year":"2010","unstructured":"Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension. 2010;55(5):1217\u201323. \n                      https:\/\/doi.org\/10.1161\/hypertensionaha.109.147058\n                      \n                    .","journal-title":"Hypertension"},{"issue":"6","key":"893_CR30","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1161\/hypertensionaha.112.201186","volume":"60","author":"J Brinkmann","year":"2012","unstructured":"Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension. 2012;60(6):1485\u201390. \n                      https:\/\/doi.org\/10.1161\/hypertensionaha.112.201186\n                      \n                    .","journal-title":"Hypertension"},{"issue":"2","key":"893_CR31","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1161\/circulationaha.110.971580","volume":"123","author":"H Krum","year":"2011","unstructured":"Krum H, Sobotka P, Mahfoud F, Bohm M, Esler M, Schlaich M. Device-based antihypertensive therapy: therapeutic modulation of the autonomic nervous system. Circulation. 2011;123(2):209\u201315. \n                      https:\/\/doi.org\/10.1161\/circulationaha.110.971580\n                      \n                    .","journal-title":"Circulation"},{"issue":"4","key":"893_CR32","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1007\/s11906-015-0532-6","volume":"17","author":"BW Petkovich","year":"2015","unstructured":"Petkovich BW, Vega J, Thomas S. Vagal modulation of hypertension. Curr Hypertens Rep. 2015;17(4):532. \n                      https:\/\/doi.org\/10.1007\/s11906-015-0532-6\n                      \n                    .","journal-title":"Curr Hypertens Rep"},{"issue":"8","key":"893_CR33","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1038\/nrcardio.2015.96","volume":"12","author":"RG Victor","year":"2015","unstructured":"Victor RG. Carotid baroreflex activation therapy for resistant hypertension. Nat Rev Cardiol. 2015;12(8):451\u201363. \n                      https:\/\/doi.org\/10.1038\/nrcardio.2015.96\n                      \n                    .","journal-title":"Nat Rev Cardiol"},{"issue":"1","key":"893_CR34","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2174\/15701611113119990142","volume":"12","author":"G Grassi","year":"2014","unstructured":"Grassi G, Seravalle G, Brambilla G, Cesana F, Giannattasio C, Mancia G. Similarities and differences between renal sympathetic denervation and carotid baroreceptor stimulation. Curr Vasc Pharmacol. 2014;12(1):63\u20138.","journal-title":"Curr Vasc Pharmacol"},{"issue":"15","key":"893_CR35","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"\u2022 Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370(15):1393\u2013401. \n                      https:\/\/doi.org\/10.1056\/NEJMoa1402670\n                      \n                    . This study is the first randomized controlled study evaluating renal denervation in the USA. This study was different from prior trials in that control subjects were masked and underwent a sham procedure.","journal-title":"N Engl J Med"},{"issue":"8","key":"893_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jash.2014.06.001","volume":"8","author":"M Esler","year":"2014","unstructured":"Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J Am Soc Hypertens. 2014;8(8):593\u20138. \n                      https:\/\/doi.org\/10.1016\/j.jash.2014.06.001\n                      \n                    .","journal-title":"J Am Soc Hypertens"},{"issue":"7","key":"893_CR37","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jacc.2014.05.037","volume":"64","author":"F Mahfoud","year":"2014","unstructured":"Mahfoud F, Edelman ER, Bohm M. Catheter-based renal denervation is no simple matter: lessons to be learned from our anatomy? J Am Coll Cardiol. 2014;64(7):644\u20136. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2014.05.037\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"893_CR38","doi-asserted-by":"publisher","first-page":"240","DOI":"10.14797\/mdcj-11-4-240","volume":"11","author":"MG Denker","year":"2015","unstructured":"Denker MG, Cohen DL. Resistant hypertension and renal nerve denervation. Methodist DeBakey Cardiovasc J. 2015;11(4):240\u20134. \n                      https:\/\/doi.org\/10.14797\/mdcj-11-4-240\n                      \n                    .","journal-title":"Methodist DeBakey Cardiovasc J"},{"key":"893_CR39","doi-asserted-by":"crossref","unstructured":"Kandazari DE, Kario K, Mahfoud F, Cohen SA. The SPYRAL HTN Global Clinical Trial Program: rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. 2016;171(1):82\u201391.","DOI":"10.1016\/j.ahj.2015.08.021"},{"issue":"10108","key":"893_CR40","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/s0140-6736(17)32281-x","volume":"390","author":"RR Townsend","year":"2017","unstructured":"\u2022\u2022 Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160\u201370. \n                      https:\/\/doi.org\/10.1016\/s0140-6736(17)32281-x\n                      \n                    . This is the proof-of-concept trial using the Spyral catheter that suggests that ablating renal nerves can reduce blood pressure in patients with untreated mild-to-moderate hypertension.","journal-title":"Lancet"},{"issue":"10137","key":"893_CR41","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"David E Kandzari","year":"2018","unstructured":"\u2022\u2022 Kandzari DE, Bohm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018; \n                      https:\/\/doi.org\/10.1016\/s0140-6736(18)30951-6\n                      \n                    . This is the proof-of-concept trial using the Spyral catheter that demonstrated the safety and efficacy of catheter-based renal denervation in patients with uncontrolled hypertension on antihypertensive treatment.","journal-title":"The Lancet"},{"issue":"1","key":"893_CR42","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1161\/hypertensionaha.114.04336","volume":"65","author":"S Ewen","year":"2015","unstructured":"Ewen S, Ukena C, Linz D, Kindermann I, Cremers B, Laufs U, et al. Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension. Hypertension. 2015;65(1):193\u20139. \n                      https:\/\/doi.org\/10.1161\/hypertensionaha.114.04336\n                      \n                    .","journal-title":"Hypertension"},{"key":"893_CR43","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/S0140-6736(13)62192-3","volume":"383","author":"H Krum","year":"2014","unstructured":"Krum H, Schlaich M, Sobotka P, Bohm M, Mahfoud F, et al. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study. Lancet. 2014;383:622\u20139. \n                      https:\/\/doi.org\/10.1016\/S0140-6736(13)62192-3\n                      \n                    .","journal-title":"Lancet"},{"key":"893_CR44","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"M Azizi","year":"2018","unstructured":"\u2022\u2022 Azizi M, Schmeider R, Mahfoud F, Weber M. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a muticentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335\u201345. This is a single-blind, randomized, proof-of-concept study indicating that, among patients with mild to moderate hypertension on no medications, renal denervation with the Paradise endovascular ultrasound renal denervation system results in a greater reduction in both SBP and DBP at 2\u00a0months compared with a sham procedure.","journal-title":"Lancet"},{"key":"893_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ahj.2017.09.006","volume":"195","author":"L Mauri","year":"2018","unstructured":"Mauri L, Kario K, Basile J, Daemen J, Davies J, Kirtane AJ, et al. A multinational clinical approach to assessing the effectiveness of catheter-based ultrasound renal denervation: the RADIANCE-HTN and REQUIRE clinical study designs. Am Heart J. 2018;195:115\u201329. \n                      https:\/\/doi.org\/10.1016\/j.ahj.2017.09.006\n                      \n                    .","journal-title":"Am Heart J"},{"issue":"1","key":"893_CR46","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1586\/17434440.5.1.33","volume":"5","author":"IJ Scheffers","year":"2008","unstructured":"Scheffers IJ, Kroon AA, Tordoir JH, de Leeuw PW. Rheos Baroreflex Hypertension Therapy System to treat resistant hypertension. Expert Rev Med Devices. 2008;5(1):33\u20139. \n                      https:\/\/doi.org\/10.1586\/17434440.5.1.33\n                      \n                    .","journal-title":"Expert Rev Med Devices"},{"issue":"7","key":"893_CR47","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","volume":"58","author":"JD Bisognano","year":"2011","unstructured":"Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal Trial. J Am Coll Cardiol. 2011;58(7):765\u201373. \n                      https:\/\/doi.org\/10.1016\/j.jacc.2011.06.008\n                      \n                    .","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"893_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jash.2012.01.003","volume":"6","author":"GL Bakris","year":"2012","unstructured":"Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6(2):152\u20138. \n                      https:\/\/doi.org\/10.1016\/j.jash.2012.01.003\n                      \n                    .","journal-title":"J Am Soc Hypertens"},{"key":"893_CR49","doi-asserted-by":"publisher","first-page":"587194","DOI":"10.1155\/2012\/587194","volume":"2012","author":"T Alnima","year":"2012","unstructured":"Alnima T, de Leeuw PW, Kroon AA. Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract. 2012;2012:587194\u20137. \n                      https:\/\/doi.org\/10.1155\/2012\/587194\n                      \n                    .","journal-title":"Cardiol Res Pract"},{"issue":"4","key":"893_CR50","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jash.2012.04.004","volume":"6","author":"UC Hoppe","year":"2012","unstructured":"Hoppe UC, Brandt MC, Wachter R, Beige J, Rump LC, Kroon AA, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270\u20136. \n                      https:\/\/doi.org\/10.1016\/j.jash.2012.04.004\n                      \n                    .","journal-title":"J Am Soc Hypertens"},{"issue":"5","key":"893_CR51","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.jacbts.2016.06.004","volume":"1","author":"K Narkiewicz","year":"2016","unstructured":"\u2022 Narkiewicz K, Ratcliffe LE, Hart EC, Briant LJ, Chrostowska M, Wolf J, et al. Unilateral carotid body resection in resistant hypertension: a safety and feasibility trial. JACC Basic Transl Sci. 2016;1(5):313\u201324. \n                      https:\/\/doi.org\/10.1016\/j.jacbts.2016.06.004\n                      \n                    . This is the proof-of-concept study for unilateral carotid body resection involving 15 patients with resistant hypertension.","journal-title":"JACC Basic Transl Sci"},{"issue":"Suppl_1","key":"893_CR52","doi-asserted-by":"publisher","first-page":"ehx504.4123","DOI":"10.1093\/eurheartj\/ehx504.4123","volume":"38","author":"P Neuzil","year":"2017","unstructured":"Neuzil P, Reddy V, Malek F, Kmonicek P, Sievert H, Zeller T, et al. Long term effect of transvenous carotid body ablation in the treatment of patients with resistant hypertension. Eur Heart J. 2017;38(Suppl_1):ehx504.4123.","journal-title":"Eur Heart J"},{"issue":"e-Supplement 2","key":"893_CR53","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1097\/01.hjh.0000523143.97845.cc","volume":"35","author":"Schlaich","year":"2017","unstructured":"Schlaich, et al. J Hypertens. 2017;35(e-Supplement 2):e64.","journal-title":"J Hypertens"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11906-018-0893-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-018-0893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T19:03:47Z","timestamp":1567796627000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11906-018-0893-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,7]]},"references-count":53,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["893"],"URL":"https:\/\/doi.org\/10.1007\/s11906-018-0893-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734001148.793571593","asserted-by":"object"}]},"ISSN":["1522-6417","1534-3111"],"issn-type":[{"value":"1522-6417","type":"print"},{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,7]]},"assertion":[{"value":"7 September 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Dr. Hinderliter receives grant support from ReCor Medical for participation in the RADIANCE-HTN trial. Dr. Voora declares no conflicts of interest relevant to this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"92"}}